Assessing whether serum ceruloplasmin promotes non-alcoholic steatohepatits via regulating iron metabolism
Abstract
Introduction: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD). At present, the diagnostic gold standard for detecting NASH still relies upon an invasive pathological biopsy. There is therefore a need to identify non-invasive diagnostic markers. Oxidative stress mediates fatty liver progression to NASH. Imbalanced iron metabolism produces a large amount of reactive oxygen species (ROS). Ceruloplasmin is associated with oxidase and iron metabolism-related activities. The current study aimed to determine whether there was a correlation between ceruloplasmin levels and NASH, and whether such a relationship may be associated with altered iron metabolism in NASH patients.
Materials and Methods: A total of 135 NAFLD patients were enrolled in this study, and a pathological biopsy confirmed that 60 of these patients had NAFLD activity scores (NAS) ≥ 5, while the remaining 75 had NAS < 5.
Results: Receiver operating characteristic (ROC) curves confirmed that serum ceruloplasmin and ferritin levels were predictors of NAS ≥ 5 and NAS < 5, with area under the curve (AUC) values of 0.80 and 0.81, respectively. The serum ceruloplasmin levels in NAS ≥ 5 patients were significantly lower than those in NAS < 5 patients (p < 0.001). Serum ceruloplasmin levels were also negatively correlated with ferritin levels, and lower serum ceruloplasmin levels were associated with more severe histopathological findings.
Conclusion: Low serum ceruloplasmin and high serum ferritin are correlated with NASH, and low serum ceruloplasmin may be associated with NASH owing to its ability to increase iron load.
References
2. Ahmed A, Wong RJ and Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 2015; 13: 2062-70.
3. Ludwig J, Viggiano TR, Mcgill DB and Oh B. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-38.
4. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-53.
5. Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol 2018; 113: 1649-59.
6. Day CP and James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842-45.
7. Buzzetti E, Pinzani M and Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-48.
8. Novo E and Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis & tissue repair 2008; 1: 1-58.
9. Yoneda M, Nozaki Y, Endo H, Mawatari H, Iida H, et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci 2010; 55: 808-14.
10. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander‐Tetri BA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77-85.
11. Brown MA, Stenberg LM and Mauk AG. Identification of catalytically important amino acids in human ceruloplasmin by site‐directed mutagenesis. FEBS Lett 2002; 520: 8-12.
12. Bento I, Peixoto C, Zaitsev VN and Lindley PF. Ceruloplasmin revisited: structural and functional roles of various metal cation-binding sites. Acta Crystallogr D Biol Crystallogr 2007; 63: 240-48.
13. Gitlin J. Transcriptional regulation of ceruloplasmin gene expression during inflammation. J Biol Chem 1988; 263: 6281-87.
14. Smith MA, Nunomura A, Zhu X, Takeda A and Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxidants and Redox Signaling 2000; 2: 413-20.
15. Sokolov AV, Acquasaliente L, Kostevich VA, Frasson R, Zakharova ET, et al. Thrombin inhibits the anti-myeloperoxidase and ferroxidase functions of ceruloplasmin: relevance in rheumatoid arthritis. Free Radic Biol Med 2015; 86: 279-94.
16. Cabassi A, Binno SM, Tedeschi S, Ruzicka V, Dancelli S, et al. Low serum ferroxidase I activity is associated with mortality in heart failure and related to both peroxynitrite-induced cysteine oxidation and tyrosine nitration of ceruloplasmin. Circ Res 2014; 114: 1723-32.
17. Kleiner D, Brunt E, Van Natta Mf, Behling C, Contos M, et al. Nonalcoholic Steatohepatitis Clinical Research Network Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
18. Goh GB, Issa D, Lopez R, Dasarathy S, Dasarathy J, et al. The development of a non‐invasive model to predict the presence of non‐alcoholic steatohepatitis in patients with non‐alcoholic fatty liver disease. J Gastroenterol Hepatol 2016; 31: 995-1000.
19. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-58.
20. Chen L, Xiong S, She H, Lin SW, Wang J, et al. Iron causes interactions of TAK1, p21ras, and phosphatidylinositol 3-kinase in caveolae to activate IκB kinase in hepatic macrophages. J Biol Chem 2007; 282: 5582-88.
21. Tsukamoto H. Iron regulation of hepatic macrophage TNFα expression. Free Radic Biol Med 2002; 32: 309-13.
22. Babitt JL and Lin HY. The molecular pathogenesis of hereditary hemochromatosis. Semin Liver Dis 2011; 31: 280-92.
23. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19.
24. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-50.
25. Stoj C and Kosman DJ. Cuprous oxidase activity of yeast Fet3p and human ceruloplasmin: implication for function. FEBS Lett 2003; 554: 422-26.
26. Osaki S. Kinetic studies of ferrous ion oxidation with crystalline human ferroxidase (ceruloplasmin). J Biol Chem 1966; 241: 5053-59.
27. Osaki S, Johnson DA and Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1966; 241: 2746-51.
28. Lee GR, Nacht S, Lukens JN and Cartwright G. Iron metabolism in copper-deficient swine. The Journal of clinical investigation 1968; 47: 2058-69.
29. Pfeiffenberger J, Gotthardt DN, Herrmann T, Seeßle J, Merle U, et al. Iron metabolism and the role of HFE gene polymorphisms in W ilson disease. Liver International 2012; 32: 165-70.
Copyright (c) 2022 Xiong Sheng, Ziqiang Xia, Liang Zheng, Endian Zheng, Wenyi Jin, Jinming Wu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.